Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31149381 | 0.79 | ATAD2 (0.38) | KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL19267556 | 0.76 | KDM4E (0.45) | KDM4EALDH1A1LMNAHTTMAPT | |
| SCHEMBL21604703 | 0.73 | KDM4E (0.33) | KDM4EALDH1A1LMNAALOX15HTT | |
| SCHEMBL16806047 | 0.71 | KDM4E (0.51) | KDM4EALDH1A1LMNAALOX15HTT | |
| SCHEMBL10642137 | 0.69 | ALOX15 (0.59) | KDM4EALDH1A1LMNAALOX15HTT | |
| SCHEMBL20874722 | 0.69 | HSD17B10 (0.47) | KDM4EALDH1A1LMNAALOX15HTT | |
| SCHEMBL31587437 | 0.68 | KDM4E (0.39) | KDM4EALDH1A1LMNAALOX15HTT | |
| SCHEMBL21539307 | 0.68 | ACACB (0.39) | KDM4EALDH1A1LMNAALOX15HTT | |
| SCHEMBL24463268 | 0.64 | KDM4E (0.51) | KDM4EALDH1A1LMNAALOX15HTT | |
| SCHEMBL31753089 | 0.64 | HTT (0.34) | ALOX15HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019243528-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |